US 11,999,773 B2
Anti-BCMA chimeric antigen receptors
Yi Zhang, Gaithersburg, MD (US); C. Andrew Stewart, Frederick, MD (US); Metin Kurtoglu, Bethesda, MD (US); Murat V. Kalayoglu, Silver Spring, MD (US); and Michael S. Singer, Chestnut Hill, MA (US)
Assigned to Cartesian Therapeutics, Inc., Gaithersburg, MD (US)
Filed by Cartesian Therapeutics, Inc., Gaithersburg, MD (US)
Filed on Dec. 2, 2021, as Appl. No. 17/540,947.
Application 17/540,947 is a continuation of application No. 17/156,407, filed on Jan. 22, 2021, granted, now 11,220,535.
Application 17/156,407 is a continuation of application No. 16/825,996, filed on Mar. 20, 2020, granted, now 10,934,337.
Application 16/825,996 is a continuation of application No. PCT/US2020/022671, filed on Mar. 13, 2020.
Claims priority of provisional application 62/819,068, filed on Mar. 15, 2019.
Prior Publication US 2022/0089678 A1, Mar. 24, 2022
This patent is subject to a terminal disclaimer.
Int. Cl. C07K 16/28 (2006.01); A61K 39/395 (2006.01); C07K 14/705 (2006.01); C07K 16/30 (2006.01); A61K 39/00 (2006.01); C07K 14/715 (2006.01)
CPC C07K 14/70517 (2013.01) [A61K 39/3955 (2013.01); A61K 39/39558 (2013.01); C07K 16/2878 (2013.01); C07K 16/2896 (2013.01); C07K 16/30 (2013.01); A61K 2039/505 (2013.01); C07K 2317/24 (2013.01); C07K 2317/31 (2013.01); C07K 2317/53 (2013.01); C07K 2317/565 (2013.01); C07K 2317/622 (2013.01); C07K 2317/73 (2013.01); C07K 2317/76 (2013.01); C07K 2319/03 (2013.01)] 10 Claims
 
1. A protein comprising an antigen-binding portion, wherein the antigen-binding portion is an anti-B-Cell Maturation Antigen (BCMA) binding domain comprising:
a heavy chain complementarity determining region 1 (CDRH1) comprising any one of SEQ ID NOs: 1-3;
a heavy chain complementarity determining region 2 (CDRH2) comprising any one of SEQ ID NOs: 4-6;
a heavy chain complementarity determining region 3 (CDRH3) comprising any one of SEQ ID NOs: 7-9;
a light chain complementarity determining region 1 (CDRL1) comprising SEQ ID NO: 11;
a light chain complementarity determining region 2 (CDRL2) comprising any one of SEQ ID NOs: 12-15; and
a light chain complementarity determining region 3 (CDRL3) comprising any one of SEQ ID NOs: 16-18.